title: Differential flotation centrifugation study of hepatitis C virus and response to interferon therapy.
abstract: Hepatitis C virus (HCV) appears to circulate in various forms such as native virion, immune complexes, and nucleocapsids during chronic infections. To determine the association of the physicochemical properties of HCV and its response to interferon therapy in patients with chronic hepatitis C, we examined pretreatment serum samples from 43 patients with HCV RNA who had received interferon therapy, using differential flotation centrifugation in a NaCl solution with a density of 1.063 g/ml. After centrifugation, the ratio of HCV RNA in the top and bottom fractions was determined by the polymerase chain reaction and expressed as T/B. Patients with a sustained response to IFN therapy were found to have higher T/B ratios than transient responders who relapsed after treatment (P < 0.01) and nonresponders (P < 0.01). With regards to HCV genotypes, patients with genotype 1b had higher T/B ratios in the sustained response group than in the nonsustained response groups (P = 0.001), but patients with genotype 2 had a similar distribution of T/B among the 3 response groups (not significant). These findings indicate that the physicochemical properties of HCV affect the effectiveness of interferon therapy, particularly in patients with genotype 1b.
authors.affiliation: Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Nagasaka
authors.forename: S
authors.initials: S
authors.lastname: Hige
authors.forename: T
authors.initials: T
authors.lastname: Matsushima
authors.forename: J
authors.initials: J
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
authors.forename: I
authors.initials: I
authors.lastname: Tsunematsu
authors.forename: M
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002498:Centrifugation; D005260:Female; D016174:Hepacivirus / Q000737:chemistry* / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000276:immunology / Q000628:therapy / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha